Navigation Links
SyntheMed Appoints Corinne Mundin as Director, International Market Development
Date:7/18/2008

ISELIN, N.J., July 18 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today the appointment of Ms. Corinne Mundin to the newly-created position of Director, International Market Development. Ms. Mundin, who is based in England, brings more than 20 years of sales, sales management and market development experience in the medical device industry including 10 years in the cardiac surgery product segment. Most recently, she served as Director of International Sales for Novadaq Technologies Inc., a diagnostic equipment company focused on cardiac surgery, and held previous international sales management positions with Chase Medical LLP and Guidant CVS. Ms. Mundin's responsibilities will include enhancing the company's distributor network, establishing corporate relationships with key accounts, and increasing surgeon awareness of the benefits that REPEL-CV(R) Adhesion Barrier, the company's novel anti-adhesion product, can provide in reducing adhesion formation after open heart surgery.

Marc R. Sportsman, SyntheMed's vice president of sales, stated, "We are extremely pleased that Corinne has joined the SyntheMed team and we are confident she will positively impact our sales growth in European and other international markets. Her experience and knowledge of international medical device markets will be critically important as we continue our efforts to establish and improve our distribution channels and increase market penetration."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surround tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure. There are an estimated 500,000 open heart surgeries performed annually in the United States, and another 350,000 estimated in the European Union. In both markets, approximately 15-20 percent of these surgeries are secondary procedures.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions that form between the surface of the heart and the inner surface of the sternum. REPEL-CV is designed to provide the therapeutic benefit and then degrade, so that it is cleared from the surgical site. REPEL-CV has received CE Mark and Health Canada regulatory approvals which allow for the product to be sold in most international markets.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. The Company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
2. SyntheMed to Present at 2007 Lazard Capital Markets Fourth Annual Healthcare Conference
3. SyntheMed, Inc. Adopts Shareholder Rights Plan
4. WorldHeart Appoints David Pellone Chief Financial Officer
5. Novo Nordisk Appoints New Leader of North American Business
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. Resonant Medical Appoints New Vice President of Global Sales
9. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... the profession and recognize veterinarians’ global impact on public health. The World Veterinary ... each year, and this year have selected continuing education with a One Health ...
(Date:4/30/2016)... ... ... of us, but there are things we can do to improve the odds of staying healthy ... more that there are simple, yet important steps that can be taken to maintain good health ... for her patients include;, , exercise , healthy diet ...
(Date:4/29/2016)... York (PRWEB) , ... April 30, 2016 , ... Mercy ... Ferry campus. The following programs will be expanding due to high demand: Master ... The expansion will begin this summer. , School of Business Graduate ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: